Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EK6P
|
|||
| Former ID |
DNC000006
|
|||
| Drug Name |
(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate
|
|||
| Synonyms |
(2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid; (2R,4R)-APDC; (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid; 169209-63-6; 2R,4R-APDC; CHEMBL40086; CHEBI:40139; EN300-88063; 2R, 4R-APDC monohydrate; 52A; 4-amino-2,4-pyrrolidinedicarboxylic acid; AC1NSJRT; AC1Q4UAD; SCHEMBL158843; 2R, 4R-APDC; (2R,3R)-APDC; GTPL1392; CTK0E5090; DTXSID10415500; MolPort-003-982-102; BDBM50052398; ZINC32628523; SBB067830; MFCD16875409; AKOS015916056; AKOS015854214; RTC-065564; FCH3884669; NCGC00025040-02; LY314593; AJ-85443; SC-48823; TC-065564; B6634
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H10N2O4
|
|||
| Canonical SMILES |
C1C(NCC1(C(=O)O)N)C(=O)O
|
|||
| InChI |
1S/C6H10N2O4/c7-6(5(11)12)1-3(4(9)10)8-2-6/h3,8H,1-2,7H2,(H,9,10)(H,11,12)/t3-,6-/m1/s1
|
|||
| InChIKey |
XZFMJVJDSYRWDQ-AWFVSMACSA-N
|
|||
| CAS Number |
CAS 169209-63-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7978587, 11056185, 15120503, 24276926, 26744280, 26752104, 39340717, 57359309, 75240015, 90343729, 91744841, 99223623, 103216567, 103949275, 114154977, 117518359, 118315296, 126594410, 127305654, 127305655, 127305656, 127305657, 127305658, 129762234, 131301572, 131400559, 134339562, 134339599, 135635420, 135649704, 137264922, 141428213, 143439230, 151993633, 152055475, 162449345, 164830906, 176224839, 180666389, 204433876, 223594614, 226522464, 241182231, 251875150
|
|||
| ChEBI ID |
CHEBI:40139
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 2 (mGluR2) | Target Info | Agonist | [1], [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glutamatergic synapse | ||||
| Cocaine addiction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group II pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci. 2002 Dec;116(6):1075-83. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1392). | |||
| REF 3 | Attenuation of seizures induced by homocysteic acid in immature rats by metabotropic glutamate group II and group III receptor agonists. Brain Res. 2001 Jul 27;908(2):120-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.